EU General Court rejects industry’s...The European Medicines Agency (EMA) has won a landmark battle about the amount of data from clinical dossiers that may be made public. The European Court of Justics (EJC) rejected the demand of three … more ➔
FIND funding diagnostics to fight AMRGlobal health product development partnership FIND (Foundation for Innovative New Diagnostics) has announced four major diagnostics projects to combat antimicrobial resistance (AMR) in resource-poor … more ➔
Cancer is a gate-opener to data sharingA brand-new survey conducted by auditing and consulting firm PwC and Strategy& has found out that 80% of data protection-prone Germans would share their data in case of being diagnosed with cancer. … more ➔
Bacterial duo triggers colorectal cancerUS and Dutch researchers have found that carcinogenic E. coli and B. fragilis versions in the gut of patients who developed precancerous polyps early in life trigger development of colon cancer … more ➔
CRISPR corrects clustered DMD mutationsUsing CRISPR-Cas 9 genome editing, US and German stem cell researchers have corrected clustered mutations in the dystrophin gene in heart mucle cells obtained from induced pluripotent stem cells of patients … more ➔
EPO bows to pressure from industryFollowing critisism from the industry, the European Patent Office has drafted a proposal to allow exemptions to its Early Certainty Initiative. Industry associations had pressed the EPO not to limit … more ➔
Sanofi acquiring AblynxBriefly after Belgian nanobody maker Ablynx rejected a €2.3bn take-over bid of Novo, its board accepted a €3.9bn tender of its R&D partner Sanofi. It’s the second large take-over of Sanofi this … more ➔
EMA recommends seven new drugs for market The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) greenlighted seven medicines for approval at its January 2018 meeting, including one orphan medicine, and one biosimilar. more ➔
Bacterium blocks dengue and Zika virus tra... Scientists at the University of Glasgow have found a bacterial strain which blocks dengue and Zika virus transmission from mosquitoes. more ➔
Novartis in US$170m licence deal with Spar...Novartis AG has strengthened its ophtalmology portfolio by acquiring a licence for Spark Therapeutics’ voretigene neparvovec (Luxturna), an FDA-approved gene therapy that corrects mutations in RPE65, … more ➔
